Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Court Rules Against Sanofi's Patent Litigation | Contract Pharma

What are you searching for?

Sign in
Breaking News

Court Rules Against Sanofi’s Patent Litigation

The U.S. District Court for the District of New Jersey has ruled against Sanofi-Aventis in its U.S. Eloxatin patent litigation, granting judgment in favor of several generic companies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The U.S. District Court for the District of New Jersey has ruled against Sanofi-Aventis in its U.S. Eloxatin patent litigation, granting judgment in favor of several generic companies. SA plans to appeal this decision, which if upheld could result in an earlier-than-expected launch of generic Eloxatin in the U.S.

Under the judgment, Hospira’s version of the chemotherapy medication does not infringe on the original. Hospira is anticipating FDA approval shortly for its generic version of Eloxatin. Teva Pharmaceutical Industries also has a version of the drug, which is awaiting FDA approval.

Eloxatin, known generically as oxaliplatin, had more than $1.8 billion in sales in 2008 for Sanofi.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters